What's New on the Wound Care Horizon?
•
0 likes•561 views
This document discusses emerging technologies in wound care, focusing on hyperbaric oxygen therapy, advanced cell-based therapies using mesenchymal stem cells and bioengineered skin substitutes, and intermittent pneumatic compression devices. It reviews evidence that hyperbaric oxygen therapy significantly increases wound healing rates compared to placebo treatment. New cell-based therapies utilize fibroblasts, keratinocytes, and mesenchymal stem cells from sources like bone marrow and amniotic membrane to reduce inflammation and promote proliferation, angiogenesis, and collagen deposition. Intermittent pneumatic compression enhances lymphatic return, arterial perfusion, and oxygen delivery to wounds.
Recommended
More Related Content
Similar to What's New on the Wound Care Horizon?
Similar to What's New on the Wound Care Horizon? (20)
More from Jennifer Gerres, DPM
More from Jennifer Gerres, DPM (7)
Recently uploaded
Recently uploaded (20)
What's New on the Wound Care Horizon?
- 1. 9/4/13 1 What’s New on the Wound Care Horizon? Georgeanne Botek, DPM FACFAS Orthopaedic and Rheumatologic Institute WHAT’S NEW on the WOUND CARE HORIZON
- 2. 9/4/13 2 WHAT’S NEW on the WOUND CARE HORIZON • Cost • Products • Modalities
- 3. 9/4/13 3 WHAT’S NEW on the WOUND CARE HORIZON WHAT’S NEW on the WOUND CARE HORIZON Wound Healing Moisture Balance Perfusion Offloading Infec8on Control Edema Control
- 4. 9/4/13 4 1980s 1990s 2000s 2010s WOUND CARE TIMELINE Wet-‐to-‐Dry Dressings Silver Dressings Advanced Biologics Arterial Perfusion Bioengineered Skin products Total Contact Cast Hydrocolloids Subatmospheric Pressure (VAC) Regranex Hyperbaric Oxygen Accuzyme, Panafil PRFE Ultrasound HYPERBARIC OXYGEN • Increases Oxygen • Enhances Perfusion • Reduces Edema • Controls Inflamma8on • Promotes: – Fibroblast Prolifera8on – Collagen Deposi8on – Angiogenesis • An8microbial Ac8vity • Mobilizes stem cells
- 5. 9/4/13 5 PITFALLS of HYPERBARIC OXYGEN • Availability • Cost – $50,000 to $200,000 • Time Consuming – 60 hours • Pa8ent Percep8on • Adverse effects • Is it worth it? HYPERBARIC OXYGEN: EVIDENCE Significantly healed ulcers in the short term, but long term benefit unproven. Major amputaLon may be reduced, but lacked staLsLcal significance Cochrane Library April 2012
- 6. 9/4/13 6 HYPERBARIC OXYGEN EVIDENCE • 94 pa8ents randomized • Pa8ent baseline similar – Average age: 68 – DM dura8on: 21 years – Ulcer: • Most Wagner 3-‐4 • 10 month dura8on • 55% had previous Vascular IntervenLon performed on affected limb Löndhal M et al. Diabetes Care 2010 HYPERBARIC OXYGEN EVIDENCE • At end of treatment: – Complete ulcer healing: 61% HBOT vs. 27% Placebo • At 1 year: – Complete ulcer healing: 52% of HBOT vs. 27% Placebo • Number Needed to Treat: 4.2 • Conclusion: – Adjunc8ve treatment that facilitates wound healing Löndhal M et al. Diabetes Care 2010
- 7. 9/4/13 7 HYPERBARIC OXYGEN EVIDENCE • Treatment (n=8) – Age: 72 – DM dura8on 12 years – Ulcer: Wagner 1 or 2 • Result: – 6 weeks: 5/8 – 1 year: 0/8 • Placebo (n=8) – Age: 70 – DM dura8on: 10 years – Ulcer: Wagner 1 or 2 • Result: – 6 weeks 1/8 – 1 year: 0/8 Abidia A et al. Eur J Vasc Endovasc Surg 2003 1980s 1990s 2000s 2010s WOUND CARE TIMELINE Wet-‐to-‐Dry Dressings Silver Dressings Advanced Biologics Bioengineered Skin products Total Contact Cast Hydrocolloids Subatmospheric Pressure (VAC) Regranex Hyperbaric Oxygen Accuzyme, Panafil PRFE Ultrasound Arterial Perfusion
- 8. 9/4/13 8 ADVANCED CELL-‐BASED TECHNOLOGIES • Fibroblasts – Grown on an absorbable mesh – With kera8nocytes grown on bovine collagen • STSG harvested from human cadavers • Growth factors • Decellularized collagen materials – Ac8ng as scaffolds – fetal bovine 8ssues Bioengineered Skin Subs8tutes: MESENCHYMAL STEM CELLS • Mul8potent cells • Self-‐renewal capacity • Sources – Bone marrow – Human placenta
- 9. 9/4/13 9 MESENCHYMAL STEM CELLS Inflamma8on • Regulate • AnLmicrobial AcLvity Prolifera8on • Cell MigraLon • Angiogenesis Remodeling • Collagen DeposiLon MESENCHYMAL STEM CELLS: AMNIOTIC MEMBRANE • Minimal Criteria – Adherence to plas8c – Fibroblast colony forma8on – Differen8a8on poten8al – Human fetal origin • 1-‐4x104 cells/cm2 • Skin subs8tutes – Fibroblasts and epithelial cells
- 10. 9/4/13 10 MESENCHYMAL STEM CELLS: AMNIOTIC MEMBRANE • Advantages: – Availability – Easy procurement – Ease of isola8on and expansion in culture prior to transplanta8on • Limita8ons: – Cost to pa8ent – Steriliza8on techniques – Collec8on – LITERATURE 1980s 1990s 2000s 2010s WOUND CARE TIMELINE Wet-‐to-‐Dry Dressings Silver Dressings Advanced Biologics Bioengineered Skin products Total Contact Cast Hydrocolloids Subatmospheric Pressure (VAC) Regranex Hyperbaric Oxygen Accuzyme, Panafil PRFE Ultrasound Arterial Perfusion
- 11. 9/4/13 11 INTERMITTENT PNEUMATIC COMPRESSION: ARTERIAL COMPRESSION PUMPS How Does It Work? • Enhances lympha8c return • Disengorges the 8ssue • Allows arterioles to open • Improves arterial perfusion • Triggers release of Nitric Oxide • Reduces edema • Oxygenates wound • Delivers inflammatory cells INTERMITTENT PNEUMATIC COMPRESSION: CIRCULATOR BOOT • Synchronized with the heartbeat • Uses a leg bag rather than cuff – Allows any por8on of leg to be treated • Limits compression pressure to diastole – Providing pressure to disseminate the arterial inflow • Can immerse the limb in bags containing an8bio8c solu8on – May help remove bioburden in the ulcers
- 12. 9/4/13 12 INTERMITTENT PNEUMATIC COMPRESSION: EVIDENCE-‐BASED MEDICINE 1. Abu-‐Own A, Cheatle T, Scurr JH, and Smith PDC: Eur J Vasc Surg 1993 2. Agerskov K, Ton HP, Jensen FB, Engell, Dan Med Bull: 1990 3. Alpagut U, Dayioglu E: Angiology. 56:19-‐23, 2005 4. Amsterdam EA, Lee G, Tonkon MJ, DeMaria AN and Mason DT: 1977 5. Bergan JJ, Sparks S, Angle N: Vascular and Endovascular Surgery 32:455-‐462, 1998 6. Blackshear WM, Pescoo C, LePain F, Benoit S, Dickstein R, Seifert KB: J Vasc Surg 5:432-‐6, 1987 7. Bolli R, Marbán E: Physiol Rev 79:609-‐34, 1999 8. Chleboun GS, Howell JN, Baker HL, Ballard TN, Graham JL, Hallman HL, Perkins LE, Schauss JH and Conatser RR: Arch Phys Med Rehabil 76:744-‐749, 1995 9. Delis KT, Nicolaides AN, Wolfe JH, Stansby G: J Vasc Surg 31:650-‐61, 2000 10. Delis KT, Nicolaides AN, Labropoulos N, Stansby G:. J Vasc Surg 32:284-‐92, 2000 11. Delis KT, Knaggs AL: J Vasc Surg 42(4): 717-‐25, 2005 12. Delis KT, Nicolaides AN: Ann Surg 241: 431-‐441, 2005 INTERMITTENT PNEUMATIC COMPRESSION: EVIDENCE-‐BASED MEDICINE 13. Dillon RS: J Clin Engineering 3:63, 1980 14. Dillon RS: Angiology 31:614-‐638, 1980 15. Dillon RS: Angiology 37: 47-‐56, 1986 16. Dillon RS: Ann Surg 204: 643-‐649, 1986 17. Dillon RS: Vasc Surg (Westerminister Press) 24: 682-‐695, 1990 18. Dillon RS: 48, Number 5, Part 2: S17-‐S34, 1997 19. Dillon RS:. Angiology 48, Number 5, part 2: S35-‐S58, 1997 20. Dillon RS: Chapter 13 in "The Wound Management Manual" pages 141-‐211. Bok Y. Lee editor. McGraw-‐Hill 2005 21. Eze AR, Comerota AJ, Cisek PL, Holland BS, Kerr RP, Veeramasuneni R and Comerota Jr. A|J: IntermiEent calf and foot compression increases lower extremity blood flow. Am J Surg 172:130-‐135, 1996 22. Filip JR, Dillon RS: Treatment of end-‐stage "trash feet" with the end-‐ diastolic pneumaMc boot. Angiology 59(2):214-‐9, 2008
- 13. 9/4/13 13 INTERMITTENT PNEUMATIC COMPRESSION: EVIDENCE-‐BASED MEDICINE 23. Ginsberg JS, Brill-‐Edwards P, Kowalchuk G, Hirsh J: Arch Intern Med 149: 1651-‐2, 1989 24. Kakkos SK, Griffin M, Geroulakos G, Nicolaides AN:. J Vasc Surg 42:296-‐303, 2005 25. Kakkos SK, Geroulakos G, Nicolaides AN: Eur J Vasc Endovasc Surg 30:164-‐75, 2005 26. Kavros SJ, Delis KT, Turner NS, Voll AE, Liedl DA, Gloviczki P, Rooke TW.: J Vasc Surg 47(3):543-‐9,2008 27. Labropoulos N, Watson WC, Mansour MA, Kang SS, Lioooy FN, Baker WH: Arch Surg 133:1072-‐5, 1998 28. Labropoulos N, Leon LR, Bhas A et al:. J Vas Surg 42:710-‐6, 2005 29. Liu K, Chen LE, Seaber AV, Urbaniak JR: J Orthop Res 17(3):415-‐20, 1999 INTERMITTENT PNEUMATIC COMPRESSION: EVIDENCE-‐BASED MEDICINE 30. McCulloch JM, Marler KC, Neal MB and Phifer TJ: Advances in Wound Care 7:22-‐26, 1994 31. Montori VM, Kavros SJ, Walsh EE, Rooke TW: Int Angiol 21(4):360-‐6. 2002 32. Morgan RH, Carolan G, Psaila JV, Gardner AMN, Fox RH and Woodcock JP: Vasc Surg 25: 8-‐15, 1991 33. Ramaswami G, D'Ayala M, Hollier LH et al: J Vasc Surg 41:794-‐801, 2005 34. Smith PC, Sarin S, Hasty J and Scurr JH: Surgery 108: 871-‐875, 1990 35. Sultan S, Esan O, Fahy A: Vascular 16: 130-‐9, 2008 36. van Bemmelen PS, Maoos MA, Faught WE, Mansour MA, Barkmeier LD, Hodgson KJ, Ramsey DE, Sumner DS: AugmentaMon of blood flow in limbs with occlusive arterial disease by intermiEent calf compression. J Vasc Surg 19:1052-‐8, 1994 37. van Bemmelen PS, Gitlitz DB et al: Arch Surg 136:1280-‐5, 2001 38. Vella A, Carlson LA, Blier B, Felty C, Kuiper JD and Rooke TW: Vascular Medicine 5:21-‐25, 2000
- 14. 9/4/13 14 INTERMITTENT PNEUMATIC COMPRESSION • Group 1 (IPC group): – 24 pa8ents, average age 70 – Post pedal amp – 85-‐95 mmHg; 3, 2-‐hour sessions • 42% BKA – Failed wound healing • Group 2 (control): – 24 pa8ents, average age 69 – Post pedal amp • 83% resulted in BKA Kavros SJ, Delis KT et al. Society for Vasc Surg 2008 Wound healing and limb salvage were significantly beZer in the IntermiZent PneumaLc Compression Group Within 18 months, 3 Lmes as many people with IPC healed their wounds and avoided BKA Kavros SJ, Delis KT et al. Society for Vasc Surg 2008 INTERMITTENT PNEUMATIC COMPRESSION
- 15. 9/4/13 15 ARTERIAL COMPRESSION PUMPS: EVIDENCE • Retrospec8ve review – 101 cases from Gonda Vascular Center at Mayo Clinic – 2 of 3 used Air Cast Arterial Flow for 6 hours at home – 1 of 3 used Circulator Boot in Wound Center for 2, 45-‐minute sessions • 47% complete wound healing Montori VM, Kavros SJ et al Int Angiology 2002 • 74 year-‐old male – Second opinion regarding right foot rest pain and wounds • 10/2008: right foot purple discolora8on • 12/2008: seen by Vascular Surgery – Angiogram: • Occlusion of the AT and PT with patent peroneal artery to the level of the foot • Recommended right BKA INTERMITTENT PNEUMATIC COMPRESSION: CASE
- 16. 9/4/13 16 PAST MEDICAL HISTORY • CAD s/p CABG LIMA-‐ LAD and SVG-‐RCA • s/p PTCA 1997 prox RCA • HTN • Hyperlipidemia • DM2 • Afib s/p DCCx2, s/p PPM • Hyperthyroidism – amiodarone induced • CKD • Right LE – ABI: 1.33 – TBI: 0.23 Recommended: • Arterial flow device to use for 6 hours a day • Aquacell AG between toes WORKUP and PLAN
- 17. 9/4/13 17 MONOPHASIC RIGHT DP, PT by DOPPLER DEPENDENT RUBOR INTERMITTENT PNEUMATIC COMPRESSION: CASE aer 6 MONTHS
- 18. 9/4/13 18 7 MONTHS aer INITIATION of ARTERIAL COMPRESSION PUMP in the HOME INTERMITTENT PNEUMATIC COMPRESSION: CASE aer 8 MONTHS
- 19. 9/4/13 19 WHAT’S NEW on the WOUND CARE HORIZON • Does it provide beoer outcomes, Watson? • Is the therapy cost effec8ve? • Is it efficient? • Technically simple? WHAT’S NEW on the WOUND CARE HORIZON • Hyperbaric Oxygen Therapy • Mesenchymal Stem Cell Therapy • Arterial Perfusion In Conclusion…